Seattle Genetics Inc. (SGEN)
-NasdaqGS 35.61 
0.12(0.34%) 01:40 SGT - Nasdaq Real Time Price
| Prev Close: | 35.73 |
|---|
| Open: | 35.76 |
|---|
| Bid: | 35.89 x 100 |
|---|
| Ask: | 35.92 x 300 |
|---|
| 1y Target Est: | 32.42 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 35.59 - 36.43 |
|---|
| 52wk Range: | 19.03 - 39.00 |
|---|
| Volume: | 384,063 |
|---|
| Avg Vol (3m): | 801,676 |
|---|
| Market Cap: | 4.32B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealedat Seeking Alpha(Wed, 22 May)
- Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AMat Seeking Alpha(Wed, 22 May)
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Playersat Motley Fool(Mon, 20 May)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Fri, 17 May)
- SGEN's Adcetris under FDA ReviewZacks(Fri, 17 May)
- SEATTLE GENETICS INC /WA FinancialsEDGAR Online Financials(Thu, 16 May)
- Seattle Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, 15 May)
- FDA accepts Seattle Genetics Adcetris applicationAP(Tue, 14 May)
- FDA accepts Seattle Genetics Adcetris applicationAP(Tue, 14 May)
- Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDABusiness Wire(Tue, 14 May)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.70 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.82 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S.
View More